Table 1 Baseline characteristics of small-cell lung cancer study population (N = 229)
Variables | Number of patients (%) | P | |
|---|---|---|---|
Limited-stage (n = 107) | Extensive-stage (n = 122) | ||
Age (year) | |||
Median (range) | 68 (43‒82) | 68 (32‒91) | 0.923 |
Gender | |||
Male | 91 (85) | 104 (85) | 0.966 |
Female | 16 (15) | 18 (15) | |
ECOG performance score | |||
0‒1 | 76 (71) | 82 (67) | 0.393 |
≥ 2 | 11 (10) | 20 (16) | |
Unknown | 20 (19) | 20 (16) | |
Ever-smoker | |||
Yes | 95 (89) | 93 (76) | 0.032 |
No | 10 (9) | 27 (22) | |
Unknown | 2 (2) | 2 (2) | |
Body mass index (kg/m2) | |||
Median (range) | 23.8 (15.4‒32.7) | 23.0 (17.1‒32.8) | 0.640 |
No. of symptoms at diagnosis | |||
Median (range) | 1 (0‒4) | 1 (0‒5) | 0.713 |
Clinical T stage | |||
T1 | 15 (14) | 5 (4) | 0.013 |
T2 | 29 (27) | 22 (18) | |
T3 | 11 (10) | 21 (17) | |
T4 | 30 (28) | 48 (39) | |
Unknown | 22 (21) | 26 (21) | |
Clinical N stage | |||
N0 | 11 (10) | 2 (2) | < 0.001 |
N1 | 9 (8) | 3 (2) | |
N2 | 42 (39) | 35 (29) | |
N3 | 43 (40) | 74 (61) | |
Unknown | 2 (2) | 8 (6) | |
Definitive treatment | |||
Chemoradiotherapya | 57 (53) | 15 (12) | < 0.001 |
Chemotherapy | 37 (35) | 99 (81) | |
Radiotherapy | 6 (6) | 5 (4) | |
Surgery (± adjuvant therapy) | 7 (6) | 3 (3) | |
Prophylactic cranial irradiation | |||
Yes | 26 (24) | 17 (14) | 0.045 |
No | 81 (76) | 105 (86) | |
Chemotherapy regimens | |||
Cisplatin-based doublet | 67 (63) | 66 (54) | 0.576 |
Carboplatin-based doublet | 27 (25) | 37 (30) | |
Others | 3 (3) | 3 (3) | |
Not available | 10 (9) | 16 (13) | |
Cycles of first-line chemotherapy | |||
< 4 | 28 (26) | 38 (31) | 0.380 |
≥ 4 | 69 (65) | 68 (56) | |
Not available | 10 (9) | 16 (13) | |
Salvage treatment | |||
Chemoradiotherapya | 15 (14) | 18 (15) | 0.910 |
Chemotherapy | 16 (15) | 22 (18) | |
Othersb | 10 (9) | 12 (10) | |
No treatment | 66 (62) | 70 (57) | |